Sec Form 3 Filing - Cryobank Holdings LLC @ Cord Blood America, Inc. - 2018-02-06

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Cryobank Holdings LLC 2. Issuer Name and Ticker or Trading Symbol Cord Blood America, Inc. [ CBAI] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 11915 LA GRANGE AVENUE 3. Date of Earliest Transaction (MM/DD/YY) 02/06/2018 (Street) LOS ANGELES, CA90025 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Cryobank Holdings LLC 11915 LA GRANGE AVENUE LOS ANGELES, CA90025 X California Cryobank LLC 11915 LA GRANGE AVENUE LOS ANGELES, CA90025 X California Cryobank Stem Cell Services LLC 11915 LA GRANGE AVENUE LOS ANGELES, CA90025 X Signatures /s/ Richard Jennings 02/16/2018 Signature of Reporting Person Date /s/ Richard Jennings 02/16/2018 Signature of Reporting Person Date /s/ Richard Jennings 02/16/2018 Signature of Reporting Person Date

Explanation of Responses:

Remarks: This statement is jointly filed by Cryobank Holdings LLC ("CCB Holdings"), California Cryobank LLC ("CCB") and California Cryobank Stem Cell Services LLC ("FamilyCord" and together with CCB Holdings and CCB, the "Reporting Persons"). On February 6, 2018, Cord Blood America, Inc. (the "Issuer"), FamilyCord and certain shareholders of the Issuer entered into a voting agreement, pursuant to which, among other things, such shareholders granted to FamilyCord an irrevocable voting proxy (the "Proxy") with respect to the 381,052,632 shares of the Issuer's common stock beneficially owned by such shareholders (such shares, collectively, the "Covered Shares"). As a result of the Proxy, the Reporting Persons share voting power with respect to the Covered Shares, but none of the Reporting Persons has, solely or together with each other or with others, investment power with respect to, or pecuniary interest in, any of the Covered Shares. Neither the filing of this statement nor any of its content shall be deemed an admission by any Reporting Person that it is the beneficial owner of any of any equity securities covered by this statement for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose, and each Reporting Person expressly disclaims beneficial ownership of all such securities.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.